129 related articles for article (PubMed ID: 36717673)
1. Predicting the HER2 status in oesophageal cancer from tissue microarrays using convolutional neural networks.
Pisula JI; Datta RR; Valdez LB; Avemarg JR; Jung JO; Plum P; Löser H; Lohneis P; Meuschke M; Dos Santos DP; Gebauer F; Quaas A; Walch A; Bruns CJ; Lawonn K; Popp FC; Bozek K
Br J Cancer; 2023 Mar; 128(7):1369-1376. PubMed ID: 36717673
[TBL] [Abstract][Full Text] [Related]
2. AutoIHC-Analyzer: computer-assisted microscopy for automated membrane extraction/scoring in HER2 molecular markers.
Tewary S; Arun I; Ahmed R; Chatterjee S; Mukhopadhyay S
J Microsc; 2021 Jan; 281(1):87-96. PubMed ID: 32803890
[TBL] [Abstract][Full Text] [Related]
3. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
[TBL] [Abstract][Full Text] [Related]
4. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
[TBL] [Abstract][Full Text] [Related]
5. Automated segmentation of cell membranes to evaluate HER2 status in whole slide images using a modified deep learning network.
Khameneh FD; Razavi S; Kamasak M
Comput Biol Med; 2019 Jul; 110():164-174. PubMed ID: 31163391
[TBL] [Abstract][Full Text] [Related]
6. BRR-Net: A tandem architectural CNN-RNN for automatic body region localization in CT images.
Agrawal V; Udupa J; Tong Y; Torigian D
Med Phys; 2020 Oct; 47(10):5020-5031. PubMed ID: 32761899
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study.
Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; ten Kate FJ
J Clin Pathol; 2014 Jan; 67(1):26-32. PubMed ID: 24043715
[TBL] [Abstract][Full Text] [Related]
8.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
9. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
[TBL] [Abstract][Full Text] [Related]
10. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
Grin A; Brezden-Masley C; Bauer S; Streutker CJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
[TBL] [Abstract][Full Text] [Related]
11.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
12. HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology.
Machado-Neves R; Vale J; Eloy C; Polónia A
Pathol Res Pract; 2020 Sep; 216(9):153090. PubMed ID: 32825958
[TBL] [Abstract][Full Text] [Related]
13. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.
Hu Y; Bandla S; Godfrey TE; Tan D; Luketich JD; Pennathur A; Qiu X; Hicks DG; Peters JH; Zhou Z
Mod Pathol; 2011 Jul; 24(7):899-907. PubMed ID: 21460800
[TBL] [Abstract][Full Text] [Related]
14. A convolution neural network with multi-level convolutional and attention learning for classification of cancer grades and tissue structures in colon histopathological images.
Dabass M; Vashisth S; Vig R
Comput Biol Med; 2022 Aug; 147():105680. PubMed ID: 35671654
[TBL] [Abstract][Full Text] [Related]
15. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma.
Gambardella V; Fleitas T; Tarazona N; Cejalvo JM; Gimeno-Valiente F; Martinez-Ciarpaglini C; Huerta M; Roselló S; Castillo J; Roda D; Cervantes A
Ann Oncol; 2019 Aug; 30(8):1254-1264. PubMed ID: 31046106
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
17. Predictive Marker: HER2 in Esophageal Adenocarcinoma.
Subasinghe D; Acott N; Kumarasinghe MP
Methods Mol Biol; 2018; 1756():119-134. PubMed ID: 29600365
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
19. HAHNet: a convolutional neural network for HER2 status classification of breast cancer.
Wang J; Zhu X; Chen K; Hao L; Liu Y
BMC Bioinformatics; 2023 Sep; 24(1):353. PubMed ID: 37730567
[TBL] [Abstract][Full Text] [Related]
20. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
